Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (REGO-SARC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01900743
Recruitment Status : Completed
First Posted : July 16, 2013
Last Update Posted : April 9, 2021
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Centre Oscar Lambret

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 16, 2020
Actual Study Completion Date : September 16, 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):